Fig. 5
From: The immune cell landscape of metastatic uveal melanoma correlates with overall survival
The impact of the tumor immune contexture on overall survival of immunotherapy-treated patients. a-c Comparison between immunotherapy-treated patients and individuals receiving other therapies in terms of (a) intra-tumoral and stromal CD4 + FoxP3+ Treg cell densities (number of cells/mm2), (b) intra-tumoral total CD4+ T cell density (number of cells/mm2), and (c) intra-tumoral CD4 + FoxP3+/CD8 + Granzyme B+ cell ratio. d Percentage of CD4 + FoxP3+ cells among total CD4+ lymphocytes, and (e) CD4 + FoxP3+/CD8 + Granzyme B+ cell ratio in the total area of immunotherapy-treated patients who were alive or death at the end of the follow-up. Floating box extends from 25th to 75th percentiles, line through the box indicates median, and bars extend from the smallest to largest values. Non-parametric Mann-Whitney statistical analysis was performed across the two groups, and significantly different data are represented by *(p < 0.05) and **(p < 0.01). f-h Kaplan-Meier overall survival curves in immunotherapy-treated patients according to (f) the stromal CD4 + FoxP3+ cell density, g the stromal CD4 + FoxP3+/CD8+ cell ratio, and (h) the percentage of CD4 + FoxP3+ cells among total CD4+ lymphocytes calculated in the stromal or intra-tumoral regions. Log-rank statistics were performed to determine significance, p values and the number of patients at risk for each time point are reported in each graph